Use of an educational support program to assist patients receiving injectable osteoporosis treatment: Experience with teriparatide

Current Medical Research and Opinion

Volumn 30, Issue 2, 2014, Pages 287-296

  Nogues, Xavier ^a   Luz Rentero, Maria ^b   Rodríguez, Alicia López ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b ELI LILLY AND COMPANY   (Spain)

^c International SOS   (Spain)

Author keywords

Compliance; Osteoporosis; Persistence; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34]; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG CONTRAINDICATION; DRUG DELIVERY DEVICE; DRUG WITHDRAWAL; EDUCATION PROGRAM; FEMALE; HUMAN; MALE; MIDDLE AGED; NEEDLE; OSTEOPOROSIS; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; SPAIN; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; ADOLESCENT; DRUG DELIVERY SYSTEM; EVALUATION STUDY; FRACTURES, BONE; MEDICATION COMPLIANCE; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TELEPHONE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; FRACTURES, BONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; SPAIN; TELEPHONE; TERIPARATIDE; YOUNG ADULT;

EID: 84893313675     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.851659     Document Type: Article

References (52)

1. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75
2. [Anonymous]. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54
3. Dominguez LJ, Scalisi R, Barbagallo M. Therapeutic options in osteoporosis. Acta Biomed 2010;81(Suppl 1):55-65
4. Confavreux CB, Canoui-Poitrine F, Schott AM, et al. Persistence at 1 year of oral antiosteoporotic drugs: A prospective study in a comprehensive health insurance database. Eur J Endocrinol 2012;166:735-41
5. Guañabens N. Factors affecting therapeitic compliance in osteoporosis. REEMO 2006;15:44-6
6. Hadji P, Claus V, Ziller V, et al. GRAND: The German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012;23:223-31
7. Landfeldt E, Ström O, Robbins S, et al. Adherence to treatment of primary osteoporosis and its association to fractures-The Swedish Adherence Register Analysis (SARA). Osteoporos Int 2012;23:433-43
8. Yu S, Burge RT, Foster SA, et al. The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 2012;23:1103-13
9. Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis-Analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012;50:315-22
10. Kanis JA, McCloskey EV, Johansson H, et al; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
11. National Osteoporosis Guideline Group (NOGG) on behalf of Bone Research Society BGS, British Orthopaedic Association, British Society of Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society, Royal College of Physicians and Society for Endocrinology. Osteoporosis-clinical guideline for prevention and treatment. 2008. Available at: Http://www.iofbonehealth. org/download/osteofound/ filemanager/iof/csa/consensus-guidelines/noggexecutive-summary.pdf. Accessed October 12, 2010
12. National Osteoporosis Foundation. Clinicians guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008
13. Hamdy RC, Baim S, Broy SB, et al. Algorithm for the management of osteoporosis. South Med J 2010;103:1009-16
14. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 2010;182:1864-73
15. Cadarette SM, Burden AM. Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 2010;22:397-403
16. Imaz I, Zegarra P, Gonzalez-Enriquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-Analysis. Osteoporos Int 2010;21:1943-51
17. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010;86:202-10
18. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: A review of the evidence. Expert Opin Pharmacother 2009;10:2303-15
19. Landfeldt E, Lundkvist J, Strom O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 2011;48:380-8
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-7
21. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: Clinical applications. JAMA 2002;288:2880-3
22. Lau E, Papaioannou A, Dolovich L, et al. Patients adherence to osteoporosis therapy: Exploring the perceptions of postmenopausal women. Can Fam Physician 2008;54:394-402
23. Newman ED, Matzko CK, Olenginski TP, et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): A novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006;17: 1428-34
24. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
25. Cook PF, Emiliozzi S, McCabe MM. Telephone counseling to improve osteoporosis treatment adherence: An effectiveness study in community practice settings. Am J Med Qual 2007;22:445-56
26. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: Results from the PERSIST study. Int J Clin Pract 2006;60:896-905
27. Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: A systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 2013; [Epub ahead of print
28. Forsteo teriparatide. European Medicines Agency, 2009
29. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002;288:2868-72
30. Foster SA, Foley KA, Meadows ES, et al. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 2011;22:551-7
31. Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: The UK experience. Osteoporos Int 2006;17:1626-9
32. Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: The French experience. Osteoporos Int 2009;20:625-30
33. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994;20:91-9
34. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: A cross-sectional survey. Osteoporos Int 2006;17:1638-44
35. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
36. Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-94
37. McCombs J, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
38. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003;14:808-13
39. Ringe JD, Christodoulakos GE, Mellstrom D, et al. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 2007;23:2677-87
40. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
41. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52
42. Zanchetta J, Hakim C, Lombas C. Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Ther Res 2004;6:470-80
43. Lindsay R, Miller P, Pohl G, et al. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2009;20:943-8
44. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008;23:1591-600
45. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
46. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30
47. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-13
48. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
49. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
50. Adachi JD, Hanley DA, Lorraine JK, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study. Clin Ther 2007;29:2055-67
51. Ziller V, Zimmermann SP, Kalder M, et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 2010;26:675-81
52. Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic intervention to improve medication regimen adherence: A large, pragmatic, randomized controlled trial. Arch Intern Med 2012;172:477-83